Diketopyrrolopyrrole-based fluorescent probe for visualizing over-expressed carboxylesterase in fever via ratiometric imaging
B Zhang, S Qin, N Wang, X Lu, J Jiao, J Zhang, W Zhao - Talanta, 2024 - Elsevier
Fever is the result of inflammation and the innate self-defense response of organisms, can
cause abnormal changes in the activity of many enzymes in organisms, including the …
cause abnormal changes in the activity of many enzymes in organisms, including the …
The hypervariable region of K-Ras4B governs molecular recognition and function
H Abdelkarim, A Banerjee, P Grudzien… - International journal of …, 2019 - mdpi.com
The flexible C-terminal hypervariable region distinguishes K-Ras4B, an important proto-
oncogenic GTPase, from other Ras GTPases. This unique lysine-rich portion of the protein …
oncogenic GTPase, from other Ras GTPases. This unique lysine-rich portion of the protein …
A carboxylesterase-activatable near-infrared phototheranostic probe for tumor fluorescence imaging and photodynamic therapy
L Li, Q Zhang, J Li, Y Tian, J Li, W Liu, H Diao - RSC advances, 2022 - pubs.rsc.org
Phototheranostic probes have been proven to be a promising option for cancer diagnosis
and treatment. However, near-infrared phototheranostic probes with specific tumor …
and treatment. However, near-infrared phototheranostic probes with specific tumor …
Mitochondrial Esterase Activity Measured at the Single Organelle Level by Nano-flow Cytometry
L Su, K Gao, Y Tian, X Xiao, C Lu, J Xu… - Analytical …, 2024 - ACS Publications
Monitoring mitochondrial esterase activity is crucial not only for investigating mitochondrial
metabolism but also for assessing the effectiveness of mitochondrial-targeting prodrugs …
metabolism but also for assessing the effectiveness of mitochondrial-targeting prodrugs …
Treatment of a mutant KRAS lung cancer cell line with polyisoprenylated cysteinyl amide inhibitors activates the MAPK pathway, inhibits cell migration and induces …
KRAS mutations are the most common oncogenic mutations in lung adenocarcinoma in
Black Americans. Polyisoprenylated Cysteinyl amide Inhibitors (PCAIs) constitute a group of …
Black Americans. Polyisoprenylated Cysteinyl amide Inhibitors (PCAIs) constitute a group of …
[HTML][HTML] Polyisoprenylated cysteinyl amide inhibitors disrupt actin cytoskeleton organization, induce cell rounding and block migration of non-small cell lung cancer
E Ntantie, J Fletcher, F Amissah, OO Salako… - Oncotarget, 2017 - ncbi.nlm.nih.gov
The malignant potential of Non-Small Cell Lung Cancer (NSCLC) is dependent on cellular
processes that promote metastasis. F-actin organization is central to cell migration, invasion …
processes that promote metastasis. F-actin organization is central to cell migration, invasion …
[HTML][HTML] Polyisoprenylated cysteinyl amide inhibitors deplete singly polyisoprenylated monomeric G-proteins in lung and breast cancer cell lines
N Tawfeeq, JMS Lazarte, Y Jin, MD Gregory… - Oncotarget, 2023 - ncbi.nlm.nih.gov
Finding effective therapies against cancers driven by mutant and/or overexpressed
hyperactive G-proteins remains an area of active research. Polyisoprenylated cysteinyl …
hyperactive G-proteins remains an area of active research. Polyisoprenylated cysteinyl …
Activation of MAP Kinase Pathway by Polyisoprenylated Cysteinyl Amide Inhibitors Causes Apoptosis and Disrupts Breast Cancer Cell Invasion
JMS Lazarte, NS Lamango - Biomedicines, 2024 - mdpi.com
Prognoses for TNBC remain poor due to its aggressive nature and the lack of therapies that
target its “drivers”. RASA1, a RAS-GAP or GTPase-activating protein whose activity inhibits …
target its “drivers”. RASA1, a RAS-GAP or GTPase-activating protein whose activity inhibits …
Synthetic Optimization and MAPK Pathway Activation Anticancer Mechanism of Polyisoprenylated Cysteinyl Amide Inhibitors
N Tawfeeq, Y Jin, NS Lamango - Cancers, 2021 - mdpi.com
Simple Summary RAS G-protein genes are frequently mutated and drive the progression of
about 30% of human cancers. Polyisoprenylated cysteinyl amide inhibitors (PCAIs) offer a …
about 30% of human cancers. Polyisoprenylated cysteinyl amide inhibitors (PCAIs) offer a …
[HTML][HTML] Disruption of actin filaments and suppression of pancreatic cancer cell viability and migration following treatment with polyisoprenylated cysteinyl amides
AT Nkembo, O Salako, RA Poku… - American journal of …, 2016 - ncbi.nlm.nih.gov
Pancreatic cancer is characterized by K-Ras mutations in over 90% of the cases. The
mutations make the tumors aggressive and resistant to current therapies resulting in very …
mutations make the tumors aggressive and resistant to current therapies resulting in very …